All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Apoferritin-mediated doxorubicin internalization through transferrin receptor 1

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F17%3A43912629" target="_blank" >RIV/62156489:43210/17:43912629 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216305:26620/17:PU128371

  • Result on the web

    <a href="https://mnet.mendelu.cz/mendelnet2017/mnet_2017_full.pdf" target="_blank" >https://mnet.mendelu.cz/mendelnet2017/mnet_2017_full.pdf</a>

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Apoferritin-mediated doxorubicin internalization through transferrin receptor 1

  • Original language description

    This work is aimed at the possibilities of targeted drug delivery into the tumour tissue. This approach can greatly reduce the otherwise serious side effects of conventional treatment - systemic toxicity. For this purpose, ubiquitous protein cage apoferritin was employed as a carrier of cytotoxic drugs. Its molecule size of 10-12 nm allows it to employ the effect of increased permeability and retention as well as to avoid renal clearance. The cellular uptake of this carrier is known to be mediated via the transferrin receptor 1 (TfR1), which is overexpressed on metabolically highly active cells, such as cancer cells. Therefore, apoferritin&apos;s ability to deliver drug molecules to site-of-action was tested using cell lines with high, medium and low expression of TfR1. The optimal conditions for studying the expression of TfR1 using western blotting were as follows: lysate of 50,000 cells applied in non-reducing non-denaturing buffer and the concentration of the primary antibody of 1.0 µg/mL. The properties of encapsulated doxorubicin were not affected by apoferritin, thus preserving its toxicity for cells with high level of TfR1expression (30% growth inhibition of these cells after 24 h of treatment). The suitable usage of apoferritin as a nanocarrier for chemotherapeutic delivery was confirmed in this work.

  • Czech name

  • Czech description

Classification

  • Type

    D - Article in proceedings

  • CEP classification

  • OECD FORD branch

    10608 - Biochemistry and molecular biology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2017

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Article name in the collection

    MendelNet 2017: Proceedings of International PhD Students Conference

  • ISBN

    978-80-7509-529-9

  • ISSN

  • e-ISSN

    neuvedeno

  • Number of pages

    6

  • Pages from-to

    894-899

  • Publisher name

    Mendelova univerzita v Brně

  • Place of publication

    Brno

  • Event location

    Brno

  • Event date

    Nov 8, 2017

  • Type of event by nationality

    WRD - Celosvětová akce

  • UT code for WoS article

    000440194500160